These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 16524061)

  • 1. [Immunosuppression for kidney transplant recipients: current strategies].
    Alberú J; Urrea EM
    Rev Invest Clin; 2005; 57(2):213-24. PubMed ID: 16524061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
    Lindenfeld J; Miller GG; Shakar SF; Zolty R; Lowes BD; Wolfel EE; Mestroni L; Page RL; Kobashigawa J
    Circulation; 2004 Dec; 110(25):3858-65. PubMed ID: 15611389
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immunossupresive drugs in renal transplantation].
    Baczkowska T; Durlik M
    Pol Arch Med Wewn; 2004 Oct; 112 Spec No():99-120. PubMed ID: 15669207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
    Leichtman AB
    N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
    [No Abstract]   [Full Text] [Related]  

  • 5. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.
    Tsai SF; Cheng CY; Shu KH; Wu MJ
    Transplant Proc; 2012 Jan; 44(1):190-2. PubMed ID: 22310612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
    Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
    Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
    Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
    BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current State of Immunosuppression: Past, Present, and Future.
    Karam S; Wali RK
    Crit Rev Eukaryot Gene Expr; 2015; 25(2):113-34. PubMed ID: 26080606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimizing calcineurin inhibitor drugs in renal transplantation.
    Flechner SM
    Transplant Proc; 2003 May; 35(3 Suppl):118S-121S. PubMed ID: 12742481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.
    Chang SH; Russ GR; Chadban SJ; Campbell S; McDonald SP
    Nephrology (Carlton); 2008 Apr; 13(2):171-6. PubMed ID: 18275507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunosuppressive treatment].
    Niaudet P
    Nephrol Ther; 2011 Dec; 7(7):592-8. PubMed ID: 22118788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Toward an evidence-based immunosuppression].
    Pascual J
    Nefrologia; 2001; 21(6):524-5; discussion 526-7. PubMed ID: 11881421
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H; Ross H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization.
    Smith JM; Nemeth TL; McDonald RA
    Pediatr Transplant; 2004 Oct; 8(5):445-53. PubMed ID: 15367279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.
    Pescovitz MD; Govani M
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S16-21. PubMed ID: 11583940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants.
    Mueller XM
    Ann Thorac Surg; 2004 Jan; 77(1):354-62. PubMed ID: 14726104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid-free maintenance immunosuppression with rapamune and low-dose neoral in pancreas transplant recipients.
    Rajab A; Pelletier RP; Ferguson RM; Elkhammas EA; Bumgardner GL; Henry ML
    Transplantation; 2007 Nov; 84(9):1131-7. PubMed ID: 17998868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.